Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection
Irina Tcherepanova, Jason Harris, Aijing Starr, Jaclyn Cleveland, Helen Ketteringham, David Calderhead, Joe Horvatinovich, Don Healey, Charles A Nicolette, Irina Tcherepanova, Jason Harris, Aijing Starr, Jaclyn Cleveland, Helen Ketteringham, David Calderhead, Joe Horvatinovich, Don Healey, Charles A Nicolette
Abstract
Background: Effective therapy for HIV-infected individuals remains an unmet medical need. Promising clinical trials with dendritic cell (DC)-based immunotherapy consisting of autologous DC loaded with autologous virus have been reported, however, these approaches depend on large numbers of HIV virions to generate sufficient doses for even limited treatment regimens.
Methodology/principal findings: The present study describes a novel approach for RT-PCR amplification of HIV antigens. Previously, RT-PCR amplification of autologous viral sequences has been confounded by the high mutation rate of the virus which results in unreliable primer-template binding. To resolve this problem we developed a multiplex RT-PCR strategy that allows reliable strain-independent amplification of highly polymorphic target antigens from any patient and requires neither viral sequence data nor custom-designed PCR primers for each individual. We demonstrate the application of our RT-PCR process to amplify translationally-competent RNA encoding regions of Gag, Vpr, Rev and Nef. The products amplified using this method represent a complex mixture of autologous antigens encoded by viral quasispecies. We further demonstrate that DCs electroporated with in vitro-transcribed HIV RNAs are capable of stimulating poly-antigen-specific CD8+ T cell responses in vitro.
Conclusion/significance: This study describes a strategy to overcome patient to patient viral diversity enabling strain-independent RT-PCR amplification of RNAs encoding sequence divergent quasispecies of Gag, Vpr, Rev and Nef from small volumes of infectious plasma. The approach allows creation of a completely autologous therapy that does not require advance knowledge of the HIV genomic sequences, does not have yield limitations and has no intact virus in the final product. The simultaneous use of autologous viral antigens and DCs may provoke broad patient-specific immune responses that could potentially induce effective control of viral loads in the absence of conventional antiretroviral drug therapy.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Ogg GS, Kostense S, Klein MR, Jurriaans S, Hamann D, et al. Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression. J Virology. 1999;73:9153–9160.
- Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991–998.
- Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha A, et al. Cytotoxic T' Lymphocytes in Asymptomatic Long-Term Nonprogressing HIV-1 Infection. The journal of Imrnunohgy. 1996;156:2616–2623.
- Evans DT, O'Connor DH, Jing P, Dzuris JL, Sidney J, et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med. 1999;5:1270–1276.
- Zanussi S, Simonelli C, D'Andrea M, Caffau C, Clerici M, et al. CD8+ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection. Clin Exp Immunol. 1996;105:220–224.
- Gamberg J, Pardoe I, Bowmer MI, Howley C, M. G. Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol Cell Biol. 2004;82:38–46.
- Garber DA, Silvestri G, Feinberg MB. Prospects for and AIDS vaccine: three big questions, no easy answers. The Lancet. 2004;4:397–413.
- McMichael AJ. HIV vaccines. Annual Rev Immunol. 2006;24:227–255.
- Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature. 2001;410:1002–1007.
- Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, et al. Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. J Exp Med. 2001;193:169–180.
- Goulder PJR, Walker BD. The great escape-AIDS viruses and immune control. Mature Medicine. 1999;5:1233–1235.
- Goulder PJR, I. Watkins D. HIV AND SIV CTL ESCAPE: IMPLICATIONS FOR VACCINE DESIGN. Nature. 2004;4:630–640.
- Barouch DH, Jennifer K, Kuroda MJ, Schmitz JE, Santra S, et al. Eventual AIDS vaccine failure in rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature. 2002;415:335–339.
- Garcıa F, Lejeune M, Climent N, Gil C, Alcamı J, et al. Therapeutic Immunization with Dendritic Cells Loaded with Heat-Inactivated Autologous HIV-1 in Patients with Chronic HIV-1 Infection. JID. 2005;191:1680–1685.
- Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10:1359–1365.
- Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol. 2002;21:671–678.
- Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol. 2000;164:4968–4978.
- Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol. 2002;76:10155–10168.
- Weissman D, Ni H, Scales D, Dude A, Capodici J, et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol. 2000;165:4710–4717.
- Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, et al. Vpr Is Preferentially Targeted by CTL During HIV-1 Infection1. The Journal of Immunology. 2001;167:2743–2752.
- Hel Zk, Tsai W-P, Tryniszewska E, Nacsa J, Markham PD, et al. Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes. The Journal of Immunology. 2006;176:85–96.
- Candotti D, Temple J, Owusu-Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods. 2004;118:39–47.
- Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41:4531–4536.
- Erali M, Hillyard DR. Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Microbiol. 1999;37:792–795.
- Fang G, Weiser B, Kuiken C, Philpott SM, Rowland-Jones S, et al. Recombination following superinfection by HIV-1. Aids. 2004;18:153–159.
- Scriba TJ, zur Megede J. GRH, Treurnicht FK, Barnette SW, van Rensburg EG. Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodefficiency virus type I consensus sequences. Vaccine. 2005;23:1158–1169.
- Cohen WM, Bianco A, Connan F, Camoin L, Dalod M, et al. Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1. J Virol. 2002;76:10219–10225.
- Draenert R, Allen TM, Liu Y, Wrin T, Chappey C, et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med. 2006;203:529–539.
- Su Z, Vieweg J, Weizer AZ, Dahm P, Yancey D, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 2002;62:5041–5048.
- Singh RA, Barry MA. Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J Immunol. 2004;173:4387–4393.
- Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med. 2004;10:275–281.
- Altschul SF, Madden TL, Schaffer AA, Zhang J, ZhangMiller ZW, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25:3389–3402.
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403–410.
- Christopherson C, Sninsky J, Kwok S. The effects of internal primer–template mismatches on RT-PCR: HIV-1 model studies. Nucleic Acids Research. 1997;25:654–658.
- Chang P, Cantin E, Zaia J, Ladne P, Stephens D, et al. Ribozyme-mediated site-specific cleavage of the HIV-1 genome. Clin Biotechnol. 1990;2:23–31.
- Gao F, Robertson DL, Morrison SG, Hui H, Craig S, et al. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African Origin. J Virol. 1996;70:7013–7029.
Source: PubMed